[HTML][HTML] Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in …
SM Gadgeel, JC Ruckdeschel, EI Heath… - Journal of Thoracic …, 2007 - Elsevier
Background: Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
[HTML][HTML] Gefitinib plus celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group
A Agarwala, W Fisher, D Bruetman, J McClean… - Journal of Thoracic …, 2008 - Elsevier
Background Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway,
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies …
[PDF][PDF] Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non–small-cell lung cancer
KJ O'Byrne, S Danson, D Dunlop… - Journal of clinical …, 2007 - researchgate.net
Purpose In non–small-cell lung cancer (NSCLC), the epidermal growth factor receptor
(EGFR) and cyclooxygenase-2 (COX-2) play major roles in tumorigenesis. This phase I/II …
(EGFR) and cyclooxygenase-2 (COX-2) play major roles in tumorigenesis. This phase I/II …
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non–small cell lung cancer
KL Reckamp, K Krysan, JD Morrow, GL Milne… - Clinical cancer …, 2006 - AACR
Abstract Purpose: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular
signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth …
signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth …
Retracted: Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase‐2 in nonsmall cell lung cancer may be dependent on the EGFR …
SM Gadgeel, S Ali, PA Philip, F Ahmed… - … Journal of the …, 2007 - Wiley Online Library
BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs)
have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC) …
have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC) …
Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer
KL Reckamp, M Koczywas, MC Cristea, JE Dowell… - Cancer, 2015 - Wiley Online Library
BACKGROUND Cyclooxygenase 2 (COX‐2)‐dependent signaling represents a potential
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer
M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of clinical …, 2003 - ascopubs.org
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …
Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 2
RS Herbst, G Giaccone, JH Schiller… - Journal of Clinical …, 2004 - ascopubs.org
Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington,
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance …
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance …
[HTML][HTML] Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and …
N Li, H Li, F Su, J Li, X Ma, P Gong - International journal of clinical …, 2015 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) mutations occur mostly in patients with lung
adenocarcinoma; such patients are also more likely to express cyclooxygenase-2 (COX-2) …
adenocarcinoma; such patients are also more likely to express cyclooxygenase-2 (COX-2) …
[HTML][HTML] Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer
A Santoro, R Cavina, F Latteri, PA Zucali, V Ginanni… - Annals of oncology, 2004 - Elsevier
Abstract Background Gefitinib (Iressa™, ZD1839) is an orally active, selective epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. Phase I studies showed that it is well …
growth factor receptor (EGFR) tyrosine kinase inhibitor. Phase I studies showed that it is well …